Most cited papers from Scynexis (United States)

Scynexis (United States)

What are the most cited papers from Scynexis (United States)?

The most cited paper from Scynexis (United States) is "Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond" (Wesley C. Van Voorhis et al., 2016), with 452 citations. Next come "The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation" (405) and "CNS 7056" (405).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 38 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond Wesley C. Van Voorhis et al. · PLoS Pathogens Open access187 authors	28 Jul 2016	452
2	The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation Emily L. Larkin, Christopher L. Hager, Jyotsna Chandra et al. · Antimicrobial Agents and Chemotherapy Open access	21 Feb 2017	405
3	CNS 7056 Gavin J. Kilpatrick, Margaret McIntyre, Richard F. B. Cox et al. · Anesthesiology	20 Jun 2007	405
4	The Open Access Malaria Box: A Drug Discovery Catalyst for Neglected Diseases Thomas Spangenberg, Jeremy Nicholas Burrows, Paul Kowalczyk et al. · PLoS ONE Open access	17 Jun 2013	347
5	SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis Robert T. Jacobs et al. · PLoS neglected tropical diseases Open access	28 Jun 2011	309
6	Cyclosporin A and Its Analogs Inhibit Hepatitis B Virus Entry Into Cultured Hepatocytes Through Targeting a Membrane Transporter, Sodium Taurocholate Cotransporting Polypeptide (NTCP) Koichi Watashi, Ann E. Sluder, Takuji Daito et al. · Hepatology Open access	21 Dec 2013	266
7	Fluorescent-protein biosensors: New tools for drug discovery Kenneth A. Giuliano, D. Lansing Taylor · Trends in biotechnology Review	Mar 1998	165
8	Development of Novel Drugs for Human African Trypanosomiasis Reto Brun, Robert Don, Robert T. Jacobs et al. · Future Microbiology Open access	Jun 2011	140
9	SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA ReplicationIn Vitro Sam Hopkins, Bernard Scorneaux, Zhuhui Huang et al. · Antimicrobial Agents and Chemotherapy Open access	24 Nov 2009	137
10	Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity Satomi Shimura, Koichi Watashi, Kento Fukano et al. · Journal of Hepatology Open access	25 Nov 2016	129
11	State of the Art in African Trypanosome Drug Discovery Robert T. Jacobs, Bakela Nare, Margaret A. Phillips · Current Topics in Medicinal Chemistry Open access	18 Apr 2011	129
12	Real-time molecular and cellular analysis: the new frontier of drug discovery D. Lansing Taylor, Elizabeth S. Woo, Kenneth A. Giuliano · Current Opinion in Biotechnology Review	Feb 2001	129
13	In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris Elizabeth L. Berkow, David A Angulo, Shawn R. Lockhart · Antimicrobial Agents and Chemotherapy Open access	9 May 2017	107
14	Stereocontrolled Preparation of Fully Substituted Cyclopentanes: Relevance to Total Synthesis Brian H. Heasley · European Journal of Organic Chemistry	11 Feb 2009	107
15	Application of a resazurin-based high-throughput screening assay for the identification and progression of new treatments for human African trypanosomiasis Tana Bowling, Luke Mercer, Robert Don et al. · International Journal for Parasitology Drugs and Drug Resistance Open access	6 Mar 2012	107
16	Discovery of Novel Orally Bioavailable Oxaborole 6-Carboxamides That Demonstrate Cure in a Murine Model of Late-Stage Central Nervous System African Trypanosomiasis Bakela Nare et al. · Antimicrobial Agents and Chemotherapy Open access	27 Jul 2010	105
17	Synthesis and SAR studies of very potent imidazopyridine antiprotozoal agents Tesfaye Biftu et al. · Bioorganic & Medicinal Chemistry Letters Open access	8 Feb 2006	100
18	Chemical Synthesis of the Cardiotonic Steroid Glycosides and Related Natural Products Brian H. Heasley · Chemistry - A European Journal	22 Feb 2012	99
19	Discovery of Anthelmintic Drug Targets and Drugs Using Chokepoints in Nematode Metabolic Pathways Christina M. Taylor, Qi Wang, Bruce A. Rosa et al. · PLoS Pathogens Open access	Aug 2013	99
20	A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide Manabu Kaneko, Koichi Watashi, Shinji Kamisuki et al. · Journal of Virology Open access	17 Sep 2015	98
21	Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis Stephen A. Wring, Ryan Randolph, Seonghee Park et al. · Antimicrobial Agents and Chemotherapy Open access	30 Jan 2017	96
22	The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection Sam Hopkins, Betty DiMassimo, Pamela Rusnak et al. · Journal of Hepatology	13 Mar 2012	93
23	Chalcone–Benzoxaborole Hybrid Molecules as Potent Antitrypanosomal Agents Zhitao Qiao, Qi Wang, Fenglong Zhang et al. · Journal of Medicinal Chemistry	23 Feb 2012	92
24	SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies Bernard Scorneaux, David A Angulo, Katyna Borroto–Esoda et al. · Antimicrobial Agents and Chemotherapy Open access	10 Jan 2017	91
25	Benzoxaboroles: A New Class of Potential Drugs for Human African Trypanosomiasis Robert T. Jacobs, Jacob J. Plattner, Bakela Nare et al. · Future Medicinal Chemistry	Aug 2011	91
26	De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance Cristina Jiménez‐Ortigosa, Winder B. Perez, David A Angulo et al. · Antimicrobial Agents and Chemotherapy Open access	19 Jun 2017	90
27	Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections Mahmoud Afif Ghannoum, Maiken Cavling Arendrup, Vishnu P. Chaturvedi et al. · Antibiotics Open access	25 Aug 2020	89
28	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis Andrej Spec et al. · Journal of Antimicrobial Chemotherapy	7 Jun 2019	88
29	Design, Synthesis, and Structure−Activity Relationship of Trypanosoma brucei Leucyl-tRNA Synthetase Inhibitors as Antitrypanosomal Agents Dazhong Ding, Qingqing Meng, Guangwei Gao et al. · Journal of Medicinal Chemistry	15 Feb 2011	85
30	Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis Mahmoud Afif Ghannoum, L. Long, Emily L. Larkin et al. · Antimicrobial Agents and Chemotherapy Open access	2 Apr 2018	84
31	Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species Michael A. Pfaller, Shawn A. Messer, Paul R. Rhomberg et al. · Antimicrobial Agents and Chemotherapy Open access	23 May 2017	84
32	Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303) Jane R. Schwebke, Ryan Sobel, Janet K. Gersten et al. · Clinical Infectious Diseases Open access	Sep 2021	81
33	Synthesis of Limonoid Natural Products Brian H. Heasley · European Journal of Organic Chemistry	18 Oct 2010	81
34	Why and how have drug discovery strategies in pharma changed? What are the new mindsets? Serge M. Mignani, Scot Huber, Helena Tomás et al. · Drug Discovery Today Open access	14 Sep 2015	81
35	DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis Charles E. Mowbray et al. · Journal of Medicinal Chemistry Open access	29 Oct 2021	72
36	In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations Natalie S. Nunnally, Kizee A. Etienne, David A Angulo et al. · Antimicrobial Agents and Chemotherapy Open access	4 Sep 2019	66
37	Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species Wiley A. Schell, Alexander M. Jones, Katyna Borroto–Esoda et al. · Antimicrobial Agents and Chemotherapy Open access	21 Aug 2017	65
38	AVIATR—Aerial Vehicle for In-situ and Airborne Titan Reconnaissance Jason W. Barnes et al. · Experimental Astronomy Open access	19 Dec 2011	63
39	Prediction of anti-plasmodial activity of Artemisia annua extracts: application of NMR spectroscopy and chemometrics Nigel J. C. Bailey, Yulan L. Wang, Julia Sampson et al. · Journal of Pharmaceutical and Biomedical Analysis	24 Feb 2004	62
40	The Cyclophilin Inhibitor SCY-635 Disrupts Hepatitis C Virus NS5A-Cyclophilin A Complexes Sam Hopkins, Michael D. Bobardt, Udayan Chatterji et al. · Antimicrobial Agents and Chemotherapy Open access	15 May 2012	61
41	Boron-based drugs as antiprotozoals Robert T. Jacobs, Jacob J. Plattner, Martine Keenan · Current Opinion in Infectious Diseases	15 Oct 2011	61
42	Parasite neuropeptide biology: Seeding rational drug target selection? Paul McVeigh, Louise E. Atkinson, Nikki J. Marks et al. · International Journal for Parasitology Drugs and Drug Resistance Open access	21 Nov 2011	60
43	Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata Ahmed Gamal, Sherman Chu, Thomas S. McCormick et al. · Frontiers in Cellular and Infection Microbiology Open access	11 Mar 2021	57
44	Targeting Lysine Deacetylases (KDACs) in Parasites Qi Wang, Bruce A. Rosa, Bakela Nare et al. · PLoS neglected tropical diseases Open access	24 Sep 2015	57
45	Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo‐controlled superiority study (VANISH 306) Ryan Sobel, Paul Nyirjesy, MA Ghannoum et al. · BJOG An International Journal of Obstetrics & Gynaecology Open access	21 Oct 2021	54
46	Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor James M. Apgar et al. · Bioorganic & Medicinal Chemistry Letters	4 Nov 2020	53
47	Synthesis and biological activity of imidazopyridine anticoccidial agents: Part I Andrew W. Scribner, Richard Dennis, Jean S. Hong et al. · European Journal of Medicinal Chemistry Open access	26 Feb 2007	53
48	Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections David A Angulo, Barbara Dudley Alexander, Riina Rautemaa‐Richardson et al. · Journal of Fungi Open access	25 Oct 2022	51
49	Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β- d -Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis Vidmantas Petraitis, Rūta Petraitienė, Aspasia Katragkou et al. · Antimicrobial Agents and Chemotherapy Open access	12 Mar 2020	50
50	A Novel 1,3-Beta- d -Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis Emily L. Larkin, L. Long, Nancy C. Isham et al. · Antimicrobial Agents and Chemotherapy Open access	13 Mar 2019	50

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.